Breaking News, Collaborations & Alliances

Catalent, Trizell Enter Cell Therapy Deal

Sign development and manufacturing agreement with for macrophage-based advanced cell therapy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.   Trizell’s therapeutic is an advanced therapy medicinal product (ATMP) and uses regulatory macrophages (Mregs), a platform technology developed in Germany. Initi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters